GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » Effect of Exchange Rate Changes

Avadel Pharmaceuticals (FRA:AWK) Effect of Exchange Rate Changes : €-0.2 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Effect of Exchange Rate Changes?

Avadel Pharmaceuticals's Effect of Exchange Rate Changes for the three months ended in Mar. 2025 was €0.2 Mil.

Avadel Pharmaceuticals's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.2 Mil.

Avadel Pharmaceuticals Effect of Exchange Rate Changes Historical Data

The historical data trend for Avadel Pharmaceuticals's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Effect of Exchange Rate Changes Chart

Avadel Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effect of Exchange Rate Changes
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 -0.79 -0.63 0.42 -0.61

Avadel Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effect of Exchange Rate Changes Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.03 0.47 -0.84 0.21

Avadel Pharmaceuticals Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avadel Pharmaceuticals Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » Effect of Exchange Rate Changes
Comparable Companies
COLL PAHC HROW AKBA NIKA EOLS AMPH DVAX PCRX ELTP ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
AVDL:USA
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Website
https://www.avadel.com
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.